Johnson & Johnson
NYSE:JNJ
Johnson & Johnson
Cash from Operating Activities
Johnson & Johnson
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$23.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$14.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
Zoetis Inc
NYSE:ZTS
|
Cash from Operating Activities
$2.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
20%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$3.7B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
See Also
What is Johnson & Johnson's Cash from Operating Activities?
Cash from Operating Activities
23.2B
USD
Based on the financial report for Mar 31, 2024, Johnson & Johnson's Cash from Operating Activities amounts to 23.2B USD.
What is Johnson & Johnson's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
2%
Over the last year, the Cash from Operating Activities growth was 13%. The average annual Cash from Operating Activities growth rates for Johnson & Johnson have been -1% over the past three years , 1% over the past five years , and 2% over the past ten years .